T1~T2期乳腺癌保乳术后化疗后程同步大分割放疗前瞻性Ⅰ期临床研究

目的 前瞻性评估T1~T2期乳腺癌保乳术后化疗后程大分割放疗的不良反应和耐受性，以及在缩短治疗时间、减轻患者经济负担等方面的价值。方法 共入组20例T1~T2期乳腺癌保乳术后患者，所有患者于末次多西他赛化疗前开始大分割放疗。观察急性放射反应、治疗完成率及无病生存率、住院时间及住院费用等。结果 治疗完成率100%。主要不良反应为血液学毒性（白细胞减少）及皮肤反应，患者均可耐受。中位随访时间为30.1个月，随访率100%。美容效果良好率100%。平均总治疗时间为4周，总住院治疗费用节省约1万元。21个月无病生存率为100%。结论 T1~T2期乳腺癌保乳术后可耐受同步大分割放化疗，局部控制好，美容效果佳，且具有较高的卫生经济学价值。     

盐霉素对鼻咽癌CNE-2细胞放射敏感性的影响

目的:体外实验研究盐霉素对鼻咽癌CNE-2细胞放射敏感性的影响。方法:通过CCK-8法检测盐霉素作用后鼻咽癌CNE-2细胞的增殖情况。利用克隆集落形成实验观察鼻咽癌细胞成活情况，单击多靶模型拟合剂量存活曲线，计算放射增敏指数（SER）；Chou-Talalay数学模型绘制联合指数（CI）曲线，判断盐霉素和放射的作用关系。利用γ-H2AX焦点形成检测DNA分子损伤情况。结果:盐霉素能够抑制鼻咽癌细胞的增殖，并且具有明显的时间和剂量依赖性；盐霉素作用鼻咽癌细胞的IC50值在24 h时为17.81 μmol/L，48 h时为3.98 μmol/L。根据单击多靶模型拟合细胞的存活曲线，可知在鼻咽癌细胞CNE-2中盐霉素浓度为0.1 μmol/L和0.5 μmol/L时SER分别为1.19和1.21，均大于1.0，表明盐霉素对鼻咽癌细胞具有明显的放射增敏作用。制作联合指数（CI）曲线，可知在盐霉素浓度为0.1 μmol/L时，放射剂量为2 Gy时，CI值≈1，盐霉素和放射对CNE-2的作用接近相加作用，放射剂量为4、6、8 Gy时，CI值均＜1，二者为协同作用；在盐霉素浓度为0.5 μmol/L时，放射剂量为2、4、6、8 Gy时，CI值均＜1，二者均为协同作用。相对于照射组，盐霉素+照射组能增加DNA损伤数目。结论:盐霉素能提高鼻咽癌细胞的放射敏感性，为一种潜在的放射增敏药物。     

序贯培养体系和单一培养体系对人卵母细胞受精和早期胚胎发育的影响

目的：比较在体外受精/卵胞质内单精子显微注射（IVF/ICSI）治疗周期中序贯培养体系和单一培养体系对人类早期胚胎发育的影响，为人类辅助生殖技术中胚胎培养体系的选择和评估提供参考。方法：选取155例行IVF/ICSI助孕的患者，将同一个患者的卵子分为2组，分别在Vitrolife的序贯培养体系G-IVF/G1/G2培养液（序贯培养组）和Irvine的单一培养体系CSCC培养液（单一培养组）中进行体外受精和胚胎培养，观察2组不同培养体系中胚胎受精和胚胎早期发育情况。结果：与单一培养组比较，序贯培养组受精率、双原核（2PN）受精率和多核受精率差异均无统计学意义（P>0.05）。在IVF患者中，序贯培养组和单一培养组的卵裂率、可用胚胎率、优质胚胎率和囊胚形成率比较差异均无统计学意义（P>0.05）；在ICSI患者中，序贯培养组和单一培养组的卵裂率、可用胚胎率和囊胚形成率比较差异均无统计学意义（P>0.05），但序贯培养组优质胚胎率明显高于单一培养组（P=0.015）。在IVF和ICSI患者中，单一培养组第3天胚胎致密化的比例均明显高于序贯培养组（P=0.001）。在序贯培养组中胚胎形态表面光滑均匀，单一培养组中胚胎表面较为粗糙且有颗粒状。结论：G-IVF/G1/G2序贯培养体系和CSCC单一培养体系对人卵母细胞受精和早期胚胎发育的影响无明显差异。     

Dysregulated Brain Dynamics in a Triple-Network Saliency Model of Schizophrenia and Its Relation to Psychosis

Background

Schizophrenia is a highly disabling psychiatric disorder characterized by a range of positive “psychosis” symptoms. However, the neurobiology of psychosis and associated systems-level disruptions in the brain remain poorly understood. Here, we test an aberrant saliency model of psychosis, which posits that dysregulated dynamic cross-network interactions among the salience network (SN), central executive network, and default mode network contribute to positive symptoms in patients with schizophrenia.

Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter,randomized, open-label,phase 2 trial

We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).     

胃癌术后病人肠道菌群变化及其对围手术期恢复的影响

目的探讨胃癌术后病人肠道菌群的变化及其对病人术后围手术期恢复的影响。方法选择2018年6月至2019年6月南昌大学第二附属医院胃肠外科收治的行胃癌根治术的100例病人,对每位病人术前与术后的粪便进行菌群检测(双歧杆菌、嗜酸乳杆菌、大肠杆菌、链球菌),并根据病人术后有益菌相对丰度分为丰度高组和丰度低组,同时检测病人术后生化指标(白细胞计数、中性粒细胞百分比、C反应蛋白、淋巴细胞计数、淋巴细胞百分比、总蛋白、白蛋白和前白蛋白)。结果通过高通量测序检测胃癌病人手术前后菌群变化,发现胃癌术后病人双歧杆菌、嗜酸乳杆菌明显减少,大肠杆菌、链球菌明显增多,差异有统计学意义(P<0.05)。100例病人中双歧杆菌和嗜酸乳杆菌相对丰富的病人肠道功能恢复较早,炎症指标相对较低,免疫指数有所提高,同时提高总蛋白及白蛋白营养指标,差异有统计学意义(P<0.05)。结论胃癌术后病人肠道菌群发生改变,体内有益菌双歧杆菌、嗜乳酸杆菌减少,大肠杆菌、链球菌明显增加。同时体内有益菌减少会影响病人术后恢复,增加病人炎症反应,降低机体免疫能力,影响病人营养状态。     

骨质疏松筛查系统设计与实现

目的骨质疏松症是一种起病隐匿、发病率高、治疗费用高的致残类疾病。早发现、早治疗可以显著改善骨质疏松患者的生存状态。早发现的最佳途径是通过社区医院的定期筛查,但目前市场上缺乏用于此类筛查的工具,因此亟需构建骨质疏松筛查系统。方法移动医疗的发展为解决此类问题提供了技术支持。通过提出内容可定制技术、骨质疏松临床指南数字化技术和医学化验单OCR识别技术,分别解决了筛查内容复杂多变、骨质疏松筛查知识建模和化验单图像数据结构化问题。结果基于微信小程序的MINA框架,制定了一套面向骨质疏松症筛查的便捷、轻量级解决方案,开发出"骨质疏松AI筛查防治"微信小程序,并已开展临床试用。结论此程序可方便地应用于社区筛查,提高医务人员的工作效率。